Halozyme Therapeutics, Inc. (HALO)
92.75
-0.29
(-0.31%)
USD |
NASDAQ |
Nov 20, 10:00
Halozyme Therapeutics Cash from Operations (Quarterly) : 258.27M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 258.27M |
| June 30, 2026 | 240.89M |
| March 31, 2026 | 180.08M |
| December 31, 2025 | 219.03M |
| September 30, 2025 | 178.60M |
| June 30, 2025 | 99.71M |
| March 31, 2025 | 154.22M |
| December 31, 2024 | 178.47M |
| September 30, 2024 | 115.38M |
| June 30, 2024 | 55.79M |
| March 31, 2024 | 129.43M |
| December 31, 2023 | 102.35M |
| September 30, 2023 | 132.41M |
| June 30, 2023 | 66.84M |
| March 31, 2023 | 86.96M |
| December 31, 2022 | 82.45M |
| September 30, 2022 | 69.64M |
| June 30, 2022 | 40.22M |
| March 31, 2022 | 47.80M |
| December 31, 2021 | 82.52M |
| September 30, 2021 | 121.74M |
| June 30, 2021 | 36.89M |
| March 31, 2021 | 58.30M |
| December 31, 2020 | 50.92M |
| September 30, 2020 | 6.084M |
| Date | Value |
|---|---|
| June 30, 2020 | 3.294M |
| March 31, 2020 | -4.844M |
| December 31, 2019 | -26.62M |
| September 30, 2019 | -29.59M |
| June 30, 2019 | -24.79M |
| March 31, 2019 | -4.424M |
| December 31, 2018 | 10.46M |
| September 30, 2018 | -18.93M |
| June 30, 2018 | -18.86M |
| March 31, 2018 | -22.18M |
| December 31, 2017 | 153.25M |
| September 30, 2017 | 20.26M |
| June 30, 2017 | -17.00M |
| March 31, 2017 | -22.46M |
| December 31, 2016 | -15.77M |
| September 30, 2016 | -8.748M |
| June 30, 2016 | -12.84M |
| March 31, 2016 | -13.02M |
| December 31, 2015 | -15.20M |
| September 30, 2015 | -16.98M |
| June 30, 2015 | 8.938M |
| March 31, 2015 | -13.84M |
| December 31, 2014 | -0.939M |
| September 30, 2014 | -13.18M |
| June 30, 2014 | -15.77M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -4.47M |
| AVITA Medical, Inc. | -0.6192M |
| Merck & Co., Inc. | 6.558B |
| TG Therapeutics, Inc. | 45.23M |
| Agenus, Inc. | -20.10M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 20.95M |
| Cash from Financing (Quarterly) | 587.64M |
| Free Cash Flow | 885.88M |
| Free Cash Flow Per Share (Quarterly) | 2.082 |
| Free Cash Flow to Equity (Quarterly) | -848.43M |
| Free Cash Flow to Firm (Quarterly) | 260.36M |
| Free Cash Flow Yield | 8.38% |